

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7735562
<b>Application Number:</b>	09993647
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1010
<b>Title of Invention:</b>	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
<b>First Named Inventor/Applicant Name:</b>	Bernd Riedl
<b>Customer Number:</b>	23599
<b>Filer:</b>	Csaba Henter/Caitlin Sickler
<b>Filer Authorized By:</b>	Csaba Henter
<b>Attorney Docket Number:</b>	BAYER 18A
<b>Receipt Date:</b>	03-JUN-2010
<b>Filing Date:</b>	27-NOV-2001
<b>Time Stamp:</b>	10:22:49
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P212-QUINGLONG0076-SolubleVascular.pdf	748200 <small>106cc7e9b9b0c108af6bb71d7e06538639880b7a</small>	no	8

### Warnings:

### Information:

2	NPL Documents	P213-Raez- NewDevelopmentsInChemoth erapyForAdvancedNonSmallCe llLungCancer.pdf	754899 4a9d2bdbe5f9d345f236e891b89d46c0fb8 dc0b5	no	6
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	P214-RAHMANIETAL- ApoptosisInducedbyKinaseInhi bitor.pdf	697695 082eb5a5803dbf0f26f02cd68e0479449b86 e05c	no	11
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	P215- RAKONCOGENESANGIOGENESI S.pdf	1283921 2026c3e2ef89925c1c3act0fc75230b45552a ef18	no	10
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	P216-RAK- OncogenesandTumorAngioge nesisDiffModes.pdf	1979318 arb023b605db61728002478d4b154ed1cef b1cca	no	9
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	P217-Rak1995.pdf	1931948 450644ef06e3139984395ea0f1f063268363 0feb	no	15
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	P218-Sturm- RamirezetalReemergingH5N1. pdf	1365707 1038a1e166eabd118a4ae3fa2db616e5d14 e0d74	no	10
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	P219- RaposoetalCatalysisofNucleoph ilicAdditionofPyrrolidineto2-5H .pdf	183565 3d68c4a566c859af085e38023ef5bca0bdac ca0e	no	4
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	P220-RATAINETAL- PlaceboControlled.pdf	974324 3764cd244f6adc11c1cd56b58c38087cd6 2a589	no	8
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	P221- RaviActivatedRaf-1CausesGrowt hArrestinHumanSmallCellLun gCancerCells.pdf	723840 3029bd2c8dee616a98ecf794beeb6cf37b2 c7b13	no	7
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	P222-REDDY-SorafenibRecentUpdate.pdf	29090	no	1
			15c5bd524cbe98c6f64a16d4496bf9ff282395c0		
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	P223-REDMANETAL-p38KinaseInhibitors.pdf	293632	no	4
			a848fd4b8500125737a303d06155678ed22cbf03		
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	P224-ReganPyrazoleUrea-BasedInhibitors of p38MAPKinase Form Lead Compound to Clinical Candidate.pdf	1709151	no	15
			bd0f3cf673fd0f61918fa7233d3f914b02b1bb853		
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	P225-Richly A Phase I Clinical and Pharmacokinetic Study of the Raf Kinase Inhibitor RKIBAY43-9006.pdf	243578	no	2
			9818659724aff1c539a56ef398c94ae49f72a023		
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	P226-RICHLY ETAL-Results Doxorubicin.pdf	835697	no	8
			e7b7f5d790b99abad08c4299d5d27f8f281e348d		
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	P227-Richly Results of a Phase I Trial of BAY43-9006 in Combination with Doxorubicin.pdf	139610	no	2
			2fec20c5fbf1be3b15266221b98a57f7649fd011		
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	P228-Ridley et al Action of IL-1 $\alpha$ Selectively Controlled by p38 Mitogen-Activated Protein Kinase.pdf	790358	no	9
			d1e100f5d1f5fba87a4efae747962a22c4497d88		
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	P228a-Rini and Small-J-of-Clin-Oncol-v23-n5-p1028.pdf	3962376	no	16
			6fa22f25cc5a5890efa9ee423e8a3fe1b6ce24f		
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	P228b-Robak et al Mediators of Inflammation-v12-n5-p293.pdf	393087	no	6
			e5433bd89076983675cb273a61da1d854e53a55e		
<b>Warnings:</b>					
<b>Information:</b>					

20	NPL Documents	P229- RobertsonetalHIV1Nomenclatu reproposal.pdf	463786  f542cc709bca251e2b0c6daa2b7b49bd8e8 c1d1e	no	4
----	---------------	--	--	----	---

**Warnings:**

**Information:**

**Total Files Size (in bytes):**

19503782

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**